Gubra A/S/€GUBRA

1D1W1MYTD1Y5YMAX

About Gubra A/S

Gubra A/S is a biotechnology company focused on the research and development of peptide-based therapeutics and innovative technologies for the treatment of obesity, diabetes, and related metabolic disorders. The company's core business includes providing preclinical contract research services with an emphasis on metabolic and fibrotic diseases. Gubra is headquartered in Hørsholm, Denmark. The company emphasizes its expertise in translational models and histology, supporting its unique strategic positioning in the biotech contract research space. By integrating computational biology with experimental data, Gubra aims to deliver comprehensive insights that aid in drug discovery and development.
Ticker
€GUBRA
Sector
Health
Primary listing
XGAT
Employees
330
Headquarters
Horsholm, Denmark
Website
www.gubra.dk

Gubra A/S Metrics

BasicAdvanced
€665M
-
-€1.49
0.32
-

Bulls say / Bears say

Two partnered obesity assets have reached Phase 2: BI 3034701 triggered a €10 million milestone and ABBV-295 triggered a $50 million payment after Phase 2 began. Gubra is also eligible for up to $1.875 billion in AbbVie development, commercial and sales milestones, plus royalties, giving the pipeline substantial upside without bearing all late-stage costs. (Gubra, Gubra)
GUB-UCN2 has entered a Phase 1/2a trial designed to test fat loss, muscle preservation and combination use with incretin therapies across roughly 188 participants. An external Roche/Genentech deal for another UCN2 analogue supports the commercial relevance of the CRHR2 body-composition approach, although Gubra’s own human efficacy data are still pending. (Gubra, Inderes)
CRO demand is showing early recovery: external revenue rose 11% versus H2 2025, the unit returned to positive EBIT, and management reported a sound second-half order book. This could provide a steadier base while biotech milestones remain lumpy, with 2026 CRO guidance still calling for 0–10% growth and a 10–15% EBIT margin. (Gubra)
Financial results remain highly volatile and loss-making between licensing events: H1 2026 revenue fell 95% to DKK 126 million and EBIT was negative DKK 123 million after the prior year’s AbbVie upfront payment dropped out. Biotech costs are guided at DKK 330–360 million for 2026, so cash generation depends heavily on uncertain milestone timing. (Gubra, Inderes)
GUB-UCN2 is still a first-in-class, early clinical asset with no human efficacy data; first single-ascending-dose results are not expected until H1 2027. ABBV-295’s encouraging Phase 1 weight loss came from a predominantly male, non-obese population, so whether the profile translates to broader obesity patients remains unproven. (Inderes, Gubra)
The obesity field is becoming more crowded around body-composition treatments: Roche/Genentech has licensed Hanmi’s Phase 1 UCN2 analogue acting on the same CRHR2 mechanism, creating a well-funded competitor on a similar timeline. That could reduce GUB-UCN2’s differentiation and bargaining power before Gubra reports human efficacy data. (Inderes)
Data summarised monthly by Lightyear AI. Last updated on 25 Sept 2026.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.